# ISO 5840-2:2021 (E)

### Cardiovascular implants — Cardiac valve prostheses — Part 2: Surgically implanted heart valve substitutes

performance requirements

## **Contents**

|   | Foreword  |  |  |
|---|---|--|--|
|   | Intro   | Introduction   |  |
| 1 | Sco   | Scope  |  |
| 2 | Norr  | Normative references   |  |
| 3 | Term  | Terms and definitions  |  |
| 4 | Abb   | Abbreviations  |  |
| 5 | Fund  | damental requirements  |  |
| 6 | Device description  |  |  |
|   | 6.1<br>6.2<br>6.3<br>6.3.1<br>6.3.2<br>6.3.2.1<br>6.3.2.2<br>6.3.2.3<br>6.3.2.4<br>6.3.3<br>6.4<br>6.5<br>6.6 | General<br>Intended use<br>Design inputs<br>Operational specifications<br>Performance specifications<br>General<br>Surgical heart valve substitute minimum performance requiren<br>Accessories<br>Implant procedure<br>Packaging, labelling, and sterilization<br>Design outputs<br>Design transfer (manufacturing verification/validation)<br>Risk management |  |
| 7 | Design verification and validation  |  |  |
|   | 7.1<br>7.2<br>7.2.1<br>7.2.2<br>7.2.3<br>7.2.4  | General requirements<br>In vitro assessment<br>General<br>Test conditions, sample selection, and reporting requirements<br>Material property assessment<br>Hydrodynamic performance assessment   |  |

- 7.2.5 Structural performance assessment
- 7.2.5.1 General
- 7.2.5.2
- Implant durability assessment
- 7.2.5.3 Device structural component fatigue assessment
- Component corrosion assessment 7.2.5.4
- Cavitation (rigid valves) 7.2.5.5
- Design- or procedure-specific testing 7.2.6
- General 7.2.6.1
- 7.2.6.2 Visibility
- Device MRI compatibility 7.2.7
- Simulated use 7.2.8
- Human factors/usability assessment 7.2.9
- Implant thrombogenic and haemolytic potential assessment 7.2.10
- Preclinical in vivo evaluation 7.3
- 7.3.1 General
- 7.3.2 **Overall requirements**
- Methods 7.3.3

- 7.3.4 Test report
- 7.4 Clinical investigations
- 7.4.1 General
- 7.4.2 Study considerations
- 7.4.3 Study endpoints
- 7.4.4 Ethical considerations
- 7.4.5 Pivotal studies: Distribution of subjects and investigators
- 7.4.6 Statistical considerations including sample size and duration
- 7.4.6.1 General
- 7.4.6.2 Objective performance criteria for established device designs
- 7.4.6.3 Study designs for novel devices
- 7.4.7 Patient selection criteria
- 7.4.8 Valve thrombosis prevention
- 7.4.9 Clinical data requirements
- 7.4.9.1 General
- 7.4.9.2 Baseline data
- 7.4.9.3 Peri-procedure data
- 7.4.9.4 Follow-up data
- 7.4.9.5 Clinical investigation analysis and reporting
- 7.4.9.6 Post-market clinical follow-up
- Annex A (informative) Surgical heart valve substitute hazard analysis example
  - A.1 Hazards, foreseeable sequence of events, hazardous situations, and associated harms
- Annex B (informative) In vitro procedures for testing unstented or similar valves in compliant chambers
  - B.1 General
  - B.2 Compliant chamber specifications
  - B.3 Test procedures using compliant chambers
  - B.3.1 Pulsatile-flow pressure difference
  - B.3.2 Pulsatile-flow regurgitation
  - B.3.3 Reference valves for hydrodynamic testing
  - B.3.4 Wear/durability
- Annex C (informative) Preclinical in vivo evaluation
  - C.1 General
  - C.2 Disposition of evaluations
  - C.2.1 General
  - C.2.2 Haemodynamic performance
  - C.2.3 Usability
  - C.2.4 Acoustic characteristics
  - C.2.5 Interference with adjacent anatomical structures
  - C.2.6 Haemolysis
  - C.2.7 Thrombo-embolic events
  - C.2.8 Calcification/mineralization
  - C.2.9 Pannus formation/tissue ingrowth
  - C.2.10 Structural valve deterioration and non-structural dysfunction
  - C.2.11 Assessment of valve and non-valve related pathology
  - C.2.12 Cavitation

Annex D (informative) Description of the surgical heart valve substitute and system

- D.1 General
- D.2 Chemical treatments, surface modifications, or coatings
- D.3 Component description
- D.3.1 General
- D.3.2 Examples of components of some surgical heart valve substitutes
- D.4 Accessories
- Annex E (informative) Examples of components of some surgical heart valve substitutes and systems
- Annex F (informative) Guidelines for verification of hydrodynamic performance Pulsatile flow testing
  - F.1 General
  - F.2 Pulsatile-flow testing

- F.2.1 Measuring equipment accuracy
- F.2.2 Test apparatus requirements
- F.2.3 Test procedure
- F.2.4 Test report

Annex G (informative) Examples of design specific testing

- G.1 Sewing ring integrity
- G.2 Stent creep
- G.3 Environmental degradation
- G.4 Static pressure; "burst" test
- G.5 Calcification (flexible valve)
- G.6 Particulate generation
- G.7 Effects of device post-dilatation
- G.8 Leaflet impingement force (rigid valves)
- G.9 Leaflet escape force (rigid valves)
- G.10 Sewing ring push-off
- G.11 Sewing ring torque (rigid valves)
- G.12 Device migration resistance
- Annex H (informative) Fatigue assessment
  - H.1 General
  - H.2 Fatigue crack growth, da/dN, characterization
  - H.3 Damage tolerance analysis

#### Annex I (normative) Methods of evaluating clinical data against objective performance criteria

- I.1 General
- I.2 Objective performance criteria methodology

### Annex J (normative) Adverse event classification during clinical investigation

- J.1 General
- J.2 Evaluation
- J.3 Data collection requirements
- J.4 Adverse events
- J.5 Adverse device effects
- J.6 Device deficiencies
- J.7 Classification of causal relationships
- J.8 Classification of adverse events
- J.8.1 General
- J.8.2 Examples of adverse events
- J.9 Follow up of SAEs
- J.10 Device-related mortality

Page count: 51